{
    "version": "https://jsonfeed.org/version/1.1",
    "title": "Harvard Health Posts by David M. Slovik, MD Feed",
    "home_page_url": "https://www.health.harvard.edu/authors/david-m-slovik-md",
    "feed_url": "https://www.health.harvard.edu/authors/david-m-slovik-md/feed/json",
    "language": "en-US",
    "icon": "https://www.health.harvard.edu/img/logos/hhp-logo-mark-lg.jpg",
    "items": [{
            "id": "https://www.health.harvard.edu/blog/a-new-therapy-for-osteoporosis-romosozumab-2019071717339",
            "title": "A new therapy for osteoporosis: Romosozumab",
            "url": "https://www.health.harvard.edu/blog/a-new-therapy-for-osteoporosis-romosozumab-2019071717339",
            "content_html": "Osteoporosis affects 10 million people in the United States, the majority of them women. Romosozumab is a new type of medication for treating osteoporosis that offers another treatment option for some women after menopause.",
            "summary": "Osteoporosis affects 10 million people in the United States, the majority of them women. Romosozumab is a new type of medication for treating osteoporosis that offers another treatment option for some women after menopause.",
            "date_published": "2019-07-17T14:30:45-04:00",
            "date_modified": "2019-07-17T14:30:45-04:00",
                        "authors": [                { "name": "David M. Slovik, MD" }            ],
                        "image": "https://domf5oio6qrcr.cloudfront.net/medialibrary/9849/conversions/GettyImages-1127377874-thumb.jpg",

            "tags": [ "Osteoporosis","Women's Health" ]
        }        
    ]
}